Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

(Hyoscine Butylbromide) for Abdominal Pain Associated With Cramping on Demand Basis

ClinicalTrials.gov ID: NCT00932737

Public ClinicalTrials.gov record NCT00932737. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-blind, Placebo-controlled, Randomized, Parallel-group Pilot Study of the Efficacy and Safety of Oral Doses of 20 mg Hyoscine Butylbromide When Used on Demand for the Treatment of Self-reported Functional Abdominal Pain Associated With Cramping

Study identification

NCT ID
NCT00932737
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Boehringer Ingelheim
Industry
Enrollment
197 participants

Conditions and interventions

Conditions

Interventions

  • Placebo Drug
  • HBB 20 mg Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 8, 2009
Primary completion
Feb 7, 2010
Completion
Feb 7, 2010
Last update posted
May 2, 2022

2009 – 2010

United States locations

U.S. sites
19
U.S. states
15
U.S. cities
17
Facility City State ZIP Site status
202.839.01014 Boehringer Ingelheim Investigational Site Westlake Village California
202.839.01003 Boehringer Ingelheim Investigational Site Hollywood Florida
202.839.01001 Boehringer Ingelheim Investigational Site Jupiter Florida
202.839.01002 Boehringer Ingelheim Investigational Site Jupiter Florida
202.839.01017 Boehringer Ingelheim Investigational Site Rockford Illinois
202.839.01005 Boehringer Ingelheim Investigational Site Indianapolis Indiana
202.839.01019 Boehringer Ingelheim Investigational Site Chevy Chase Maryland
202.839.01009 Boehringer Ingelheim Investigational Site Boston Massachusetts
202.839.01004 Boehringer Ingelheim Investigational Site Lebanon New Hampshire
202.839.01011 Boehringer Ingelheim Investigational Site Toms River New Jersey
202.839.01008 Boehringer Ingelheim Investigational Site Lake Success New York
202.839.01015 Boehringer Ingelheim Investigational Site Cleveland Ohio
202.839.01021 Boehringer Ingelheim Investigational Site Norman Oklahoma
202.839.01010 Boehringer Ingelheim Investigational Site Oklahoma City Oklahoma
202.839.01013 Boehringer Ingelheim Investigational Site Philadelphia Pennsylvania
202.839.01006 Boehringer Ingelheim Investigational Site San Antonio Texas
202.839.01012 Boehringer Ingelheim Investigational Site San Antonio Texas
202.839.01007 Boehringer Ingelheim Investigational Site Virginia Beach Virginia
202.839.01020 Boehringer Ingelheim Investigational Site Milwaukee Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00932737, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 2, 2022 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00932737 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →